---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-22-034294"
form_type: "8-K"
ticker: "ROIV"
cik: "0001635088"
company_name: "Roivant Sciences Ltd."
filed_at: "2022-09-21T23:59:59+00:00"
generated_at: "2026-06-23T08:18:22.265517+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Roivant terminates $250M Cantor purchase agreement, appoints new director

## Summary
- Terminated $250M Common Shares Purchase Agreement with Cantor effective by Oct 5, 2022; entered new Sales Agreement with Cowen on Sept 19, 2022.
- Director Masayo Tada resigned effective Sept 16, 2022; no dispute with company or board.
- Board appointed Hiroshi Nomura (President/CEO of Sumitomo Pharma) as Class III director effective Sept 16, 2022; waived compensation.
- At Sept 15 AGM, shareholders elected Class I directors Gline, Manchester, Epperly and ratified Ernst & Young as auditor.

## SEC filing metadata
- accession: 0001140361-22-034294
- form_type: 8-K
- ticker: ROIV
- cik: 0001635088
- company_name: Roivant Sciences Ltd.
- filed_at: 2022-09-21T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.02, 5.02, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1635088/000114036122034294/0001140361-22-034294-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1635088/000114036122034294/ny20005291x2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-22-034294
- JSON: https://secwatch.observer/filing/0001140361-22-034294.json
- Plain text: https://secwatch.observer/filing/0001140361-22-034294.txt

## Key facts
- Executive change
  Hiroshi Nomura was appointed as Class III director at Roivant Sciences Ltd..
  - Action: appointed
  - Role: Class III director
  source text: Also on September 15, 2022, the Board appointed Hiroshi Nomura to serve as a Class III director of the Board, effective September 16, 2022, filling the vacancy created by and concurrent with the resignation of Mr. Tada from the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1635088/000114036122034294/0001140361-22-034294-index.htm
- Executive change
  Masayo Tada resigned as director at Roivant Sciences Ltd..
  - Action: resigned
  - Role: director
  source text: On September 15, 2022, Masayo Tada resigned as a director of the Company, effective September 16, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1635088/000114036122034294/0001140361-22-034294-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.